Clinical response by cytogenetic risk group
| . | All patients, n = 52 . | Flu refractory, n = 43 . | Not flu refractory, n = 9 . | Complex karyotype, n = 25 . | Deletion of 17p13, n = 18 . | Deletion of 11q22, n = 21 . |
|---|---|---|---|---|---|---|
| Partial response | 21 | 17 | 4 | 9 | 7 | 15 |
| % PR | 40 | 40 | 44 | 36 | 39 | 74 |
| Median PFS, mo | 12.0 | 12.4 | 9.3 | 9.4 | 14.5 | 11.7 |
| . | All patients, n = 52 . | Flu refractory, n = 43 . | Not flu refractory, n = 9 . | Complex karyotype, n = 25 . | Deletion of 17p13, n = 18 . | Deletion of 11q22, n = 21 . |
|---|---|---|---|---|---|---|
| Partial response | 21 | 17 | 4 | 9 | 7 | 15 |
| % PR | 40 | 40 | 44 | 36 | 39 | 74 |
| Median PFS, mo | 12.0 | 12.4 | 9.3 | 9.4 | 14.5 | 11.7 |
Partial responses (PR), the PR rate, and median progression-free survival (PFS) are shown for all patients as well as for individual cytogenetic risk groups.